Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Apr-24 6:18 PM View:  | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 23-Apr-24 | Option Exercise | 130,993 | $1.06 | $138,990.00 | 1% 12.73M to 12.87M | |
| 24-Apr-24 6:17 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 23-Apr-24 | Option Exercise Duplicate | 130,993 | $1.06 | $138,990.00 | 1% 12.73M to 12.87M | |
| 22-Apr-24 7:22 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 19-Apr-24 | Option Exercise | 188,491 | $1.06 | $199,999.00 | 2% 12.55M to 12.73M | |
| 22-Apr-24 7:23 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 19-Apr-24 | Option Exercise Duplicate | 188,491 | $1.06 | $199,999.00 | 2% 12.55M to 12.73M | |
| 17-Apr-24 6:42 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 16-Apr-24 | Private Sale (Planned) Duplicate | 100,000 | $9.28 | $928,005.00 | (< 1%) 12.65M to 12.55M | |
| 17-Apr-24 6:40 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 16-Apr-24 | Private Sale (Planned) | 100,000 | $9.28 | $928,005.00 | (< 1%) 12.65M to 12.55M | |
| 10-Apr-24 5:36 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 09-Apr-24 | Private Sale (Planned) | 100,000 | $9.28 | $927,735.00 | (< 1%) 12.75M to 12.65M | |
| 10-Apr-24 5:39 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 09-Apr-24 | Private Sale (Planned) Duplicate | 100,000 | $9.28 | $927,735.00 | (< 1%) 12.75M to 12.65M | |
| 27-Mar-24 7:37 PM View: | Ra Capital Management, LLC Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 27-Mar-24 | Purchase | 505,954 | $9.79 | $4,953,290.00 | 5% 10.36M to 10.86M | |
| 27-Mar-24 7:37 PM View: | Ra Capital Management, LLC Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 26-Mar-24 | Purchase | 457,745 | $9.55 | $4,371,460.00 | 5% 9.9M to 10.36M | |
| 27-Mar-24 7:37 PM View: | Ra Capital Management, LLC Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 25-Mar-24 | Purchase | 437,600 | $9.06 | $3,964,660.00 | 5% 9.46M to 9.9M | |
| 26-Mar-24 6:48 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 25-Mar-24 | Sale (Planned) Duplicate | 95,267 | $9.12 | $869,188.00 | (< 1%) 12.84M to 12.75M | |
| 26-Mar-24 6:47 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 25-Mar-24 | Sale (Planned) | 95,267 | $9.12 | $869,188.00 | (< 1%) 12.84M to 12.75M | |
| 26-Mar-24 6:47 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 22-Mar-24 | Private Sale (Planned) | 2,343 | $9.02 | $21,134.80 | (< 1%) 12.84M to 12.84M | |
| 26-Mar-24 6:48 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 22-Mar-24 | Private Sale (Planned) Duplicate | 2,343 | $9.02 | $21,134.80 | (< 1%) 12.84M to 12.84M | |
| 21-Mar-24 9:51 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 21-Mar-24 | Sale (Planned) Duplicate | 472 | $9.00 | $4,248.00 | (< 1%) 12.84M to 12.84M | |
| 21-Mar-24 9:50 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 21-Mar-24 | Sale (Planned) | 472 | $9.00 | $4,248.00 | (< 1%) 12.84M to 12.84M | |
| 21-Mar-24 9:51 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 19-Mar-24 | Private Sale (Planned) Duplicate | 1,918 | $9.03 | $17,324.10 | (< 1%) 12.85M to 12.84M | |
| 21-Mar-24 9:50 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 19-Mar-24 | Private Sale (Planned) | 1,918 | $9.03 | $17,324.10 | (< 1%) 12.85M to 12.84M | |
| 15-Mar-24 7:52 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 15-Mar-24 | Sale (Planned) | 96,756 | $9.14 | $884,485.00 | (< 1%) 12.94M to 12.85M | |
| 15-Mar-24 7:55 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 15-Mar-24 | Sale (Planned) Duplicate | 96,756 | $9.14 | $884,485.00 | (< 1%) 12.94M to 12.85M | |
| 15-Mar-24 7:55 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 14-Mar-24 | Sale (Planned) Duplicate | 444 | $9.00 | $3,996.00 | (< 1%) 12.94M to 12.94M | |
| 15-Mar-24 7:52 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 14-Mar-24 | Sale (Planned) | 444 | $9.00 | $3,996.00 | (< 1%) 12.94M to 12.94M | |
| 15-Mar-24 7:55 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 13-Mar-24 | Private Sale (Planned) Duplicate | 2,800 | $9.00 | $25,200.00 | (< 1%) 12.95M to 12.94M | |
| 15-Mar-24 7:52 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 13-Mar-24 | Private Sale (Planned) | 2,800 | $9.00 | $25,200.00 | (< 1%) 12.95M to 12.94M | |
| 01-Mar-24 8:21 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 29-Feb-24 | Private Sale (Planned) Duplicate | 3,782 | $9.02 | $34,100.60 | (< 1%) 12.95M to 12.95M | |
| 01-Mar-24 8:17 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 29-Feb-24 | Private Sale (Planned) | 3,782 | $9.02 | $34,100.60 | (< 1%) 12.95M to 12.95M | |
| 28-Feb-24 9:04 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 28-Feb-24 | Sale (Planned) | 98,778 | $9.02 | $891,061.00 | (< 1%) 13.05M to 12.95M | |
| 28-Feb-24 9:08 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 28-Feb-24 | Sale (Planned) Duplicate | 98,778 | $9.02 | $891,061.00 | (< 1%) 13.05M to 12.95M | |
| 28-Feb-24 9:04 PM View: | Lowenthal Richard E President and CEO Director 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 26-Feb-24 | Private Sale (Planned) | 700 | $9.01 | $6,307.00 | (< 1%) 13.05M to 13.05M | |
| 28-Feb-24 9:08 PM View: | Tanimoto Sarina Chief Medical Officer 10% Owner | Ars Pharmaceuticals, Inc. (SPRY) | 26-Feb-24 | Private Sale (Planned) Duplicate | 700 | $9.01 | $6,307.00 | (< 1%) 13.05M to 13.05M | |
| 02-Oct-23 4:23 PM View: | Fitzpatrick Alexander A Chief Legal Officer | Ars Pharmaceuticals, Inc. (SPRY) | 29-Sep-23 | Purchase | 46,258 | $3.78 | $174,994.00 | 108% 42.97K to 89.23K | |
| 02-Oct-23 4:23 PM View: | Fitzpatrick Alexander A Chief Legal Officer | Ars Pharmaceuticals, Inc. (SPRY) | 28-Sep-23 | Private Purchase | 40,000 | $3.62 | $144,960.00 | 1347% 2.97K to 42.97K | |
| 25-Sep-23 4:30 PM View: | Ra Capital Management, LLC Director | Ars Pharmaceuticals, Inc. (SPRY) | 21-Sep-23 | Private Purchase | 2,700,000 | $3.03 | $8,183,530.00 | 18% 15.13M to 17.83M | |
| 05-Sep-23 8:04 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 01-Sep-23 | Option Exercise | 100,000 | $1.27 | $127,000.00 | 48% 210.35K to 310.35K | |
| 05-Sep-23 8:04 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 01-Sep-23 | Planned Option Sale | 100,000 | $7.71 | $770,520.00 | (32%) 310.35K to 210.35K | |
| 31-Aug-23 5:18 PM View: | Thompson Peter A Director | Ars Pharmaceuticals, Inc. (SPRY) | 29-Aug-23 | Purchase | 500,000 | $6.20 | $3,100,000.00 | 6% 8.74M to 9.24M | |
| 31-Aug-23 5:26 PM View: | Ra Capital Management, LLC Director | Ars Pharmaceuticals, Inc. (SPRY) | 29-Aug-23 | Purchase | 3,750,000 | $6.20 | $23,250,000.00 | 125% 3.01M to 6.76M | |
| 31-Aug-23 5:26 PM View: | Orbimed Advisors LLC Director | Ars Pharmaceuticals, Inc. (SPRY) | 29-Aug-23 | Purchase Duplicate | 500,000 | $6.20 | $3,100,000.00 | 6% 8.74M to 9.24M | |
| 07-Aug-23 5:05 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 04-Aug-23 | Planned Option Sale | 18,897 | $7.06 | $133,471.00 | (8%) 229.24K to 210.35K | |
| 07-Aug-23 5:05 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 04-Aug-23 | Option Exercise | 18,897 | $1.27 | $23,999.20 | 9% 210.35K to 229.24K | |
| 07-Aug-23 5:05 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 03-Aug-23 | Option Exercise | 26,107 | $1.27 | $33,155.90 | 12% 210.35K to 236.45K | |
| 07-Aug-23 5:05 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 03-Aug-23 | Planned Option Sale | 26,107 | $7.01 | $183,018.00 | (11%) 236.45K to 210.35K | |
| 03-Aug-23 6:03 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 02-Aug-23 | Option Exercise | 36,281 | $1.27 | $46,076.90 | 17% 210.35K to 246.63K | |
| 03-Aug-23 6:03 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 02-Aug-23 | Planned Option Sale | 36,281 | $7.09 | $257,265.00 | (15%) 246.63K to 210.35K | |
| 03-Aug-23 6:03 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 01-Aug-23 | Option Exercise | 18,715 | $1.27 | $23,768.00 | 9% 210.35K to 229.06K | |
| 03-Aug-23 6:03 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 01-Aug-23 | Planned Option Sale | 18,715 | $7.19 | $134,576.00 | (8%) 229.06K to 210.35K | |
| 07-Jul-23 8:16 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 07-Jul-23 | Option Exercise | 8,858 | $1.27 | $11,249.70 | 4% 210.35K to 219.2K | |
| 07-Jul-23 8:16 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 07-Jul-23 | Planned Option Sale | 8,858 | $6.36 | $56,372.30 | (4%) 219.2K to 210.35K | |
| 06-Jul-23 8:55 PM View: | Shawver Laura Director | Ars Pharmaceuticals, Inc. (SPRY) | 06-Jul-23 | Option Exercise | 33,510 | $1.27 | $42,557.70 | 16% 210.35K to 243.86K |
